Korro Bio (KRRO) Competitors $49.76 +1.60 (+3.32%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends KRRO vs. GLPG, XNCR, EVO, ARQT, NRIX, RCUS, KNSA, IMCR, OCUL, and MESOShould you be buying Korro Bio stock or one of its competitors? The main competitors of Korro Bio include Galapagos (GLPG), Xencor (XNCR), Evotec (EVO), Arcutis Biotherapeutics (ARQT), Nurix Therapeutics (NRIX), Arcus Biosciences (RCUS), Kiniksa Pharmaceuticals (KNSA), Immunocore (IMCR), Ocular Therapeutix (OCUL), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. Korro Bio vs. Galapagos Xencor Evotec Arcutis Biotherapeutics Nurix Therapeutics Arcus Biosciences Kiniksa Pharmaceuticals Immunocore Ocular Therapeutix Mesoblast Galapagos (NASDAQ:GLPG) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings. Do institutionals & insiders hold more shares of GLPG or KRRO? 32.5% of Galapagos shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 2.9% of Galapagos shares are held by insiders. Comparatively, 5.4% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer GLPG or KRRO? In the previous week, Galapagos had 4 more articles in the media than Korro Bio. MarketBeat recorded 6 mentions for Galapagos and 2 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.83 beat Galapagos' score of 0.42 indicating that Korro Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galapagos 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Korro Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate GLPG or KRRO? Galapagos currently has a consensus target price of $30.75, indicating a potential upside of 13.38%. Korro Bio has a consensus target price of $142.17, indicating a potential upside of 185.70%. Given Korro Bio's stronger consensus rating and higher probable upside, analysts clearly believe Korro Bio is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galapagos 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has more risk & volatility, GLPG or KRRO? Galapagos has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Is GLPG or KRRO more profitable? Galapagos' return on equity of 0.00% beat Korro Bio's return on equity.Company Net Margins Return on Equity Return on Assets GalapagosN/A N/A N/A Korro Bio N/A -50.25%-38.48% Which has stronger earnings & valuation, GLPG or KRRO? Galapagos has higher revenue and earnings than Korro Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalapagos$260.09M6.87$229.12MN/AN/AKorro Bio$14.07M33.13-$81.17MN/AN/A Does the MarketBeat Community believe in GLPG or KRRO? Galapagos received 443 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 64.10% of users gave Galapagos an outperform vote. CompanyUnderperformOutperformGalapagosOutperform Votes46664.10% Underperform Votes26135.90% Korro BioOutperform Votes23100.00% Underperform VotesNo Votes SummaryKorro Bio beats Galapagos on 9 of the 16 factors compared between the two stocks. Ad Banyan Hill PublishingTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.Click here and I’ll show you exactly how to position your money Get Korro Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRRO vs. The Competition Export to ExcelMetricKorro BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$466.15M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E RatioN/A10.75135.1917.53Price / Sales33.13287.861,232.15140.37Price / CashN/A56.6540.6537.95Price / Book2.355.394.884.92Net Income-$81.17M$152.04M$118.97M$225.78M7 Day Performance2.20%-4.32%15.41%-1.58%1 Month Performance6.71%2.80%15.47%6.67%1 Year Performance-2.66%17.30%34.58%22.48% Korro Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRROKorro Bio1.9403 of 5 stars$49.76+3.3%$142.17+185.7%-3.7%$466.15M$14.07M0.0070GLPGGalapagos0.7405 of 5 stars$26.83+0.0%$30.75+14.6%-31.6%$1.77B$260.09M0.001,123XNCRXencor4.1787 of 5 stars$24.84+3.4%$36.56+47.2%+19.7%$1.74B$168.34M-7.51280EVOEvotec1.4795 of 5 stars$4.69+4.5%$5.93+26.5%-56.6%$1.66B$777.05M0.005,061Short Interest ↓ARQTArcutis Biotherapeutics0.7957 of 5 stars$13.34+5.1%$15.50+16.2%+509.0%$1.56B$138.71M-7.58150Options VolumeNews CoverageNRIXNurix Therapeutics2.8431 of 5 stars$21.19+4.5%$30.35+43.2%+133.3%$1.50B$56.42M-6.97300RCUSArcus Biosciences2.5772 of 5 stars$16.25+1.1%$34.00+109.2%-11.3%$1.49B$117M-5.11500KNSAKiniksa Pharmaceuticals2.6661 of 5 stars$20.40+1.0%$36.60+79.4%+13.9%$1.47B$384.10M-147.36220Positive NewsIMCRImmunocore2.6216 of 5 stars$29.05+0.5%$65.64+125.9%-54.2%$1.45B$296.31M-30.43497Short Interest ↓OCULOcular Therapeutix3.797 of 5 stars$8.98+3.3%$16.71+86.1%+129.5%$1.41B$58.44M0.00267Positive NewsMESOMesoblast1.0319 of 5 stars$12.18+3.6%$11.50-5.6%+484.6%$1.39B$5.90M0.0080News CoverageGap Up Related Companies and Tools Related Companies Galapagos Alternatives Xencor Alternatives Evotec Alternatives Arcutis Biotherapeutics Alternatives Nurix Therapeutics Alternatives Arcus Biosciences Alternatives Kiniksa Pharmaceuticals Alternatives Immunocore Alternatives Ocular Therapeutix Alternatives Mesoblast Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KRRO) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
